Administration of NF-κB decoy inhibits pancreatic activation of NF-κB and prevents diabetogenesis by alloxan in mice

被引:22
|
作者
Quan, N
Ho, E
Lai, WM
Tsai, YH
Bray, T
机构
[1] Ohio State Univ, Dept Human Nutr, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Oral Biol, Columbus, OH 43210 USA
来源
FASEB JOURNAL | 2001年 / 15卷 / 07期
关键词
hyperglycemia; insulin; oxidative stress; pancreas;
D O I
10.1096/fj.00-0855fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many risk factors can trigger the development of insulin-dependent diabetes mellitus (IDDM). The induction of IDDM in vivo is strongly associated not only with the generation of reactive oxygen species but also with the activation of the transcription factor nuclear factor-kappaB (NF-kappaB). The purpose of this study was to determine the role of NF-kappaB activation in diabetogenesis. Alloxan, a diabetogenic compound that causes diabetic conditions by selectively killing the insulin-producing pancreatic beta-cells, was used as a model chemical compound to induce diabetes. We show here that the injection of alloxan in mice rapidly and specifically induced the activation of NF-kappaB in the pancreas. Intravenous administration of synthetic oligodeoxynucleotides, which are exact copies of the DNA binding site of NF-kappaB (NF-kappaB decoy), given before the alloxan injection, effectively blocked pancreatic NF-kappaB activation in mice and subsequently prevented pancreatic cell death, restored insulin secretion, and abolished hyperglycemia. Injection of scrambled NF-kappaB decoy oligodeoxynucleotides to mice had no effect on alloxan-induced diabetic conditions, These results demonstrate that NF-kappaB activation in the pancreas is required for the induction of chemically induced diabetes by alloxan.
引用
收藏
页码:1616 / +
页数:14
相关论文
共 50 条
  • [1] NF-κB inhibits β-cell death and prevents diabetes of NOD mice
    Kim, S
    Millet, I
    Cho, N
    Kim, ES
    Han, MS
    Lee, MK
    Kim, KW
    Sherwin, RS
    Lee, MS
    DIABETES, 2005, 54 : A389 - A389
  • [2] Sulindac inhibits activation of the NF-κB pathway
    Yamamoto, Y
    Yin, MJ
    Lin, KM
    Gaynor, RB
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) : 27307 - 27314
  • [3] NF-κB activation
    Abraham, E
    CRITICAL CARE MEDICINE, 2000, 28 (04) : N100 - N104
  • [4] IKKγ inhibits activation of NF-κB by NIK
    Kwon, WJ
    Kim, SH
    Park, YO
    Cho, M
    Kang, CD
    Lee, G
    An, WG
    Joo, WH
    Kim, DW
    MOLECULES AND CELLS, 2004, 18 (02) : 200 - 206
  • [5] Eriocalyxin B selectively inhibits NF-κB activity by targeting multiple steps of the NF-κB activation pathway
    Leung, Chung-Hang
    Grill, Susan P.
    Lam, Wing
    Sun, Han-Dong
    Cheng, Yung-Chi
    CANCER RESEARCH, 2006, 66 (08)
  • [6] Decoy administration of NF-κB into the subarachnoid space for cerebral angiopathy
    Ono, S
    Date, I
    Onoda, K
    Shiota, T
    Ohmoto, T
    Ninomiya, Y
    Asari, S
    Morishita, R
    HUMAN GENE THERAPY, 1998, 9 (07) : 1003 - 1011
  • [7] Selective inactivation of NF-κB in the liver using NF-κB decoy suppresses hepatic ischemia/reperfusion injury in mice
    Suzumura, K.
    Hirano, T.
    Son, G.
    Limuro, Y.
    Iiboshi, Y.
    Oh, K.
    Satake, M.
    Fujimoto, J.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S169 - S169
  • [8] Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis
    Greten, FR
    Weber, CK
    Greten, TF
    Schneider, G
    Wagner, M
    Adler, G
    Schmid, RM
    GASTROENTEROLOGY, 2002, 123 (06) : 2052 - 2063
  • [9] NF-κB activation leads to chemoresistance in pancreatic cancers B
    Baerman, KM
    Dave-Coombe, K
    Baldwin, A
    Kim, HJ
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : S86 - S86
  • [10] NF-κB, inflammation and pancreatic carcinogenesis:: NF-κB as a chemoprevention target (Review)
    Zhang, Zhiquan
    Rigas, Basil
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 29 (01) : 185 - 192